Last reviewed · How we verify
NCT07410624: Neuro-ARC
Augmented Renal Clearance in Neurocritical Care
trial in TBI (Traumatic Brain Injury) in 512 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 512 |
| Start date | 1 October 2021 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 3 locations across Canada, United States |
Conditions studied
- TBI (Traumatic Brain Injury) — all drugs for TBI (Traumatic Brain Injury) →
- Status Epilepticus — all drugs for Status Epilepticus →
- Bacterial Meningitis — all drugs for Bacterial Meningitis →
- Augmented Renal Clearance (ARC) — all drugs for Augmented Renal Clearance (ARC) →
Sponsor
University of Alberta
Who can join
Adults 18 to 85, any sex, with TBI (Traumatic Brain Injury) or Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute neurological illnesses and contribute significantly to poor outcomes if not promptly treated with appropriately dosed anti-seizure medications and antibiotics, respectively. Limited research suggested that many of those patients present with a phenomenon called augmented renal clearance (ARC) or, in other words, enhanced kidney function. ARC may have a significant influence on how medications are removed from the body potentially resulting in insufficient doses and treatment failure. Therefore, patients with ARC require higher medication doses; however, ARC is largely undetected using kidney assessment methods currently used in practice. In addition, it is not clear how medications should be dosed in those with ARC. The majority of ARC research has not focused on patients with life-threatening neurological illnesses. Thus, clinicians are likely under-dosing vital medications in those patients, and completely unaware. There is an immediate need to address the gap in knowledge. Therefore, this research aims to characterize the phenomenon of ARC in patients with life-threatening neurological illnesses through identifying the frequency, duration, contributing factors and clinical impact of ARC. Adult patients admitted to the neurosciences intensive care unit for life-threatening neurological illnesses will be enrolled in the study. Urine and blood samples wil be collected from participants to determine the presence of ARC and identify its contributing factors. In addition, blood samples will be collected from participants treated with select antibiotics and anti-seizure medications to determine their concentration and propose dose adjustment in those with ARC. This research is expected to improve the care of patients with life-threatening neurological illnesses through efficient identification and monitoring of patients exhibiting ARC facilitating timely medication dosage optimization. Furthermore, recommendations of optimal doses of commonly used medications in patients with ARC would improve the likelihood of treatment success with potential to improve patients' health and wellbeing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07410624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for TBI (Traumatic Brain Injury)
Currently open trials in the same condition.
- NCT07103200 — Evaluation of Decision-Making Fatigue After Traumatic Brain Injury · NA · recruiting
- NCT05205174 — Depth Electrode Detection of Cortical Spreading Depolarization After Traumatic Brain Injury · NA · recruiting
- NCT06867666 — Behavioral Treatment of Insomnia in Active-Duty Service Members With Traumatic Brain Injury · NA · recruiting
- NCT05327829 — Stimulating After Recovery From Traumatic Brain Injury · EARLY_PHASE1 · recruiting
- NCT06467708 — Transcutaneous Auricular Neurostimulation for ICU Patients With Traumatic Brain Injury · NA · recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07410624 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07410624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing